

### PRODUCT OBJECTIVE

The Global X S&P Biotech ETF (CURE) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the S&P Biotechnology Select Industry Index.

For informational purposes only. This document should be used to highlight some of the criteria to be used by the index provider when publishing index constituents and is not comprehensive.\*

ETF Category:  
People and Demographics

As of 15/07/2024

Index Provider: SP GLOBAL



### KEY FEATURES



High Growth Potential



Risk Controls



Targeted Exposure

## S&P BIOTECHNOLOGY SELECT INDUSTRY INDEX

### INITIAL UNIVERSE / SELECTION POOL

To qualify for membership in the index, a stock must satisfy the following criteria:

- Be a member of the S&P Total Market Index (TMI)
- Be classified as a primary stock in the S&P Select Industry Index as outline in the Membership Classification Table.
- Meet specific criteria based on float-adjusted market capitalization (FMC) and float-adjusted liquidity ratio (FALR)
  - Options include FMC  $\geq$  \$300 million with FALR  $\geq$  50%, FMC  $\geq$  \$500 million with FALR  $\geq$  90%, or FMC  $\geq$  \$400 million with FALR  $\geq$  150%.
- If fewer than 35 primary stocks qualify, additional stocks from highly correlated sub-industries may be considered, subject to FMC and liquidity criteria.
- There must be at least 35 stocks in each index after rebalancing, with potential relaxation of FMC requirements to ensure this.
- Stocks with shareholder ownership restrictions that hinder index replication may be excluded, with a one-year re-entry restriction.

### WEIGHTING SCHEME

- Constituents start with equal weights in the index.
- Each constituent's maximum weight is determined based on:
  - 4.5% of the Total Portfolio Value (TPV).
  - 4.5% of the constituent's Float-Adjusted Market Capitalization (FMC).
  - 3 times the Three-Month Median Daily Value Traded (3-month MDVT).
- Constituents' weights are capped at the lower of their initial equal weight or the calculated maximum weight.
- If the sum of initial weights exceeds 100%, excess weights are redistributed among the uncapped constituents.
- If necessary, constraints such as the maximum liquidity weight multiplier or single stock cap may be adjusted incrementally to achieve a feasible solution.
- In cases where weights exceed 4.8% for any constituent or aggregate weight constraints are breached, a secondary reweighting process may be triggered to adjust weights based on the latest available data.

### REBALANCE/REVIEWS

Rebalanced and reviewed Quarterly

*For more information on the Index, please visit S&P's website here:*

<https://www.spglobal.com/spdji/en/methodology/article/sp-select-industry-indices-methodology/>

---

\*For the complete and current index methodology please refer to the index provider's website. This summary document is accurate as of the time of its publication and Global X does not guarantee that it is current at any point thereafter.

The selection of the index constituents and their weighting is made by the index provider at its sole discretion.

Global X Management (AUS) Limited ("Global X") (Australian Financial Services Licence Number 466778, ACN 150 433 828) is the product issuer. Offers of interests in any retail product will only be made in, or accompanied by, a Product Disclosure Statement (PDS). In respect of each retail product, Global X has prepared a target market determination (TMD). Each PDS and TMD is available at [www.globalxetfs.com.au](http://www.globalxetfs.com.au). The information on this website is general in nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information, you should consider the appropriateness of the information having regard to your objectives, financial situation or needs and consider seeking independent financial, legal, tax and other relevant advice having regard to your particular circumstances. Any investment decision should only be made after obtaining and considering the relevant PDS and TMD. Investments in any product issued by Global X are subject to investment risk, including possible delays in repayment and loss of income and principal invested. The value or return of an investment will fluctuate and an investor may lose some or all of their investment. Past performance is not a reliable indicator of future performance.

Diversification does not ensure a profit nor guarantee against a loss. Brokerage commissions will reduce returns. This material represents an assessment of the market environment at a specific point in time and is not intended to be a forecast of future events, or a guarantee of future results.